Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 688 across all filing types
Latest filing 2026-05-26 Earnings Release
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva publie ses informations financières du premier trimestre 2026¹
Earnings Release Classification · 95% confidence The document is a press release (“Communiqué de Presse”) by Inventiva reporting its first-quarter 2026 financial highlights: cash, equivalents, short-term deposits, and revenue figures, with commentary on financing runway and outlook. It is not a full interim report with financial statements, but an initial announcement of quarterly results. This matches the definition of an Earnings Release (ER). Q1 2026
2026-05-26 French
Inventiva Reports 2026 First Quarter Financial Information¹
Earnings Release Classification · 85% confidence The document is a corporate press release titled “Inventiva Reports 2026 First Quarter Financial Information,” providing key highlights of Q1 financial metrics (cash balances, short‐term deposits, revenues) and upcoming milestones. It does not include full financial statements or analytical commentary typical of an interim report nor is it a mere announcement of a report’s publication. Instead, it is the initial quarterly financial results announcement, matching the definition of an Earnings Release (ER). Q1 2026
2026-05-26 English
Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference
Regulatory Filings Classification · 75% confidence The document is a press release by Inventiva announcing that its CEO will present at the 2026 Jefferies Global Healthcare Conference. It does not contain financial results, detailed presentation slides, proxy materials, or other report content. It is an announcement of an upcoming investor outreach event, which does not fit any specialized category. Therefore, it falls into the fallback category for miscellaneous regulatory/press announcements.
2026-05-21 French
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
Regulatory Filings Classification · 25% confidence The document is a press release announcing that the company’s CEO will present at an upcoming healthcare conference. It does not contain substantive financial data nor is it an actual investor slide deck or detailed report. It is an event notice that doesn’t fit into specialized categories like earnings release, management change, capital update, or investor presentation. Therefore it falls under the general regulatory announcement fallback category.
2026-05-21 English
Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing the presentation of scientific abstracts at the EASL Congress 2026. It contains no financial statements, no report attachments, no management or board changes, and is not a regulatory form itself. There is no fitting specific category, so under the fallback it is classified as a general regulatory announcement (RNS).
2026-05-13 French
Inventiva to Present Abstracts at the EASL Congress 2026
Regulatory Filings Classification · 20% confidence The document is a corporate press release announcing presentation of scientific abstracts at a medical conference. It contains no financial results, no regulatory compliance statements, no earnings or annual report data, no board or management changes, no capital/investment details. It is a generic corporate announcement and does not fit any specific category, so it falls under the fallback “Regulatory Filings” (RNS).
2026-05-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.